PPP2CB: Protein Phosphatase 2 Catalytic Subunit Beta
A core catalytic subunit of the serine/threonine phosphatase 2A (PP2A) holoenzyme, involved in cell cycle regulation, growth signaling, and tumor suppression.
Gene Information Card
| Symbol | PPP2CB |
|---|---|
| Full Name | Protein Phosphatase 2 Catalytic Subunit Beta |
| Gene Type | protein-coding |
| Chromosomal Location | 8p12 |
| NCBI Gene ID | 5516 ncbi.nlm.nih.gov/gene/5516 |
| Ensembl ID | ENSG00000104695 |
| UniProt ID | P62714 |
| OMIM ID | 176916 |
| HGNC ID | 9301 |
| Aliases | PP2A-beta, PP2CB, PP2Ac-beta |
Description
PPP2CB encodes the beta isoform of the catalytic subunit of protein phosphatase 2A (PP2A), one of the four major serine/threonine phosphatases. PP2A is a heterotrimeric holoenzyme composed of a structural A subunit, a regulatory B subunit, and a catalytic C subunit. The catalytic subunit encoded by PPP2CB is responsible for dephosphorylating key cellular substrates, thereby regulating cell cycle progression, DNA replication, transcription, apoptosis, and signal transduction pathways such as Wnt, PI3K/AKT, and MAPK. PPP2CB is widely expressed and functions as a tumor suppressor; its loss or mutation contributes to oncogenesis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Lung Cancer | Reduced PPP2CB expression or activity leads to sustained AKT and ERK signaling, promoting proliferation. | COSMIC; PMID: 25691885 |
| Breast Cancer | Somatic mutations and copy number loss of PPP2CB impair PP2A tumor suppressor function. | ClinVar; COSMIC; PMID: 28481359 |
| Colorectal Cancer | PPP2CB downregulation correlates with poor prognosis and increased beta-catenin signaling. | NCBI Gene; PMID: 23251476 |
| Prostate Cancer | Epigenetic silencing of PPP2CB contributes to PTEN-loss-driven tumorigenesis. | OMIM; PMID: 21502521 |
| Intellectual Disability | De novo missense variants in PPP2CB are associated with neurodevelopmental delay. | ClinVar; PMID: 31036916 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 14.2 | Medium |
| Heart | 9.8 | Medium |
| Liver | 7.5 | Low |
| Kidney | 11.3 | Medium |
| Lung | 10.1 | Medium |
| Breast | 8.9 | Medium |
| Colon | 12.0 | Medium |
| Prostate | 9.5 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 12.5 | High expression in embryonic kidney cells |
| HeLa | 10.8 | Moderate expression in cervical cancer cells |
| A549 | 9.2 | Lung adenocarcinoma cell line |
| MCF7 | 8.7 | Breast cancer cell line |
| HCT116 | 11.0 | Colorectal carcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | missense | <0.01% | Loss of start codon; likely loss of function |
| c.287C>T (p.Pro96Leu) | missense | <0.01% | Impaired catalytic activity; associated with intellectual disability |
| c.511G>A (p.Glu171Lys) | missense | <0.01% | Reduced PP2A activity; found in breast cancer |
| c.832C>T (p.Arg278Trp) | missense | <0.01% | Decreased substrate dephosphorylation; reported in lung cancer |
Mutation functional classification
Loss of Function (LOF)
Missense mutations (e.g., p.Pro96Leu, p.Glu171Lys) reduce catalytic activity or protein stability, impairing PP2A tumor suppressor function.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported for PPP2CB.
Dominant Negative (DN)
Heterozygous mutations (e.g., p.Arg278Trp) may interfere with holoenzyme assembly, acting in a dominant-negative manner.
View complete mutation data：
Gene Ontology (GO)
Pathways
• PP2A-mediated dephosphorylation (Reactome: R-HSA-163615)
• Signaling by Wnt (Reactome: R-HSA-195721)
• PI3K/AKT signaling (KEGG: hsa04151)
• MAPK signaling pathway (KEGG: hsa04010)
• Cell cycle (KEGG: hsa04110)
Protein Summary
The PPP2CB protein (UniProt P62714) is 309 amino acids long and belongs to the serine/threonine phosphatase family. It forms the catalytic core of the PP2A holoenzyme, which is essential for dephosphorylating a wide range of substrates including AKT, ERK, and beta-catenin. The protein contains a conserved phosphatase domain and is regulated by post-translational modifications such as methylation and phosphorylation. PPP2CB is ubiquitously expressed and its activity is critical for maintaining cellular homeostasis; dysregulation is linked to multiple cancers and neurodevelopmental disorders.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PPP2CB Knockout HEK293 Cell Line | EDJ-KQ1370 | Human | 5516 | Details Get a Quote |
| PPP2CB Knockout HCT 116 Cell Line | EDJ-KQ19523 | Human | 5516 | Details Get a Quote |
| PPP2CB Knockout A-549 Cell Line | EDJ-KQ20867 | Human | 5516 | Details Get a Quote |
| PPP2CB Knockout HeLa Cell Line | EDJ-KQ20868 | Human | 5516 | Details Get a Quote |
| PPP2CB Knockout HAP1 Cell Line | EDC09257 | Human | 5516 | Details Get a Quote |
